EY - 2015 Annual deal outlook

EY Transactions webcast

2015 Annual deal outlook

  • Share

Watch On-Demand

Confidence is high, interest rates are low, and the economy is improving. All conditions are conducive for deal-making. If M&A is not in your strategic plan for 2015, then it should be.

EY’s Capital Confidence Barometer (CCB) predicted a rise in multibillion-dollar megadeals earlier in 2014. In the latest CCB, middle market M&A is likely to be the growth engine over the next year, involving matches valued at less than $1 billion. Will the deal conditions that made 2014 a record year for US M&A continue into 2015?

On 11th February, join EY transaction professionals from the technology, oil and gas, consumer products and life sciences sectors as they discuss the current market and 2015 outlook as well as key trends such as cyber-risk and shareholder activism. Topics include:

  • What are the current deal drivers?
  • What deal size and transaction structures can we expect?
  • Which trends are impacting specific sectors?


EY - Portrait image Deborah Byers

Deborah Byers

Ernst & Young LLP

Deborah Byers is the Managing Partner of EY’s Houston office and also serves as Oil & Gas Leader for EY in the US. She is a transaction tax partner with more than 26 years of experience serving both US and non-US based multinationals with in-depth expertise on structuring and financing corporate expansions and joint ventures. She also served as the oil and gas sector leader for Americas tax and continues to be a part of the Energy Center of Excellence in Houston.

EY - Portrait image David Hedley

David Hedley

Senior Managing Director, Technology
Ernst & Young Capital Advisors, LLC

David Hedley is the Senior Managing Director, Technology for Ernst & Young Capital Advisors, LLC. David brings over 25 years of corporate finance and M&A experience to his many clients across the sector. Prior to joining EY, David worked at Canaccord Genuity, UBS Investment Bank, Thomas Weisel Partners, and Merrill Lynch & Co. David has also served on the Board of Trustees for the Morristown-Beard School for 11 years, including serving as President of the Board for two years and Chair of the Capital Campaign for three years where they raised $14 million.

EY - Portrait image Kristin Pothier

Kristin Pothier

Managing Director, Life Sciences

Kristin Pothier is the Head of Life sciences for Parthenon-EY, based in Boston. Her primary areas of focus are company and investor commercial strategy and M&A support within the Life sciences sector. With more than 20 years of experience, she has spent a majority of her career in management consulting, advising diagnostics and life sciences companies on commercial strategy and performing due diligence for both strategics and investors.

EY - Portrait image Greg Stemler

Greg Stemler

EY Global Transactions Leader, Consumer products

Greg Stemler is the EY Global Transactions Leader for the Consumer Products & Retail sector at EY.  He brings over 25 years of experience providing financial advisory and transaction advisory services to a wide variety of global clients, including an industry sector focus in branded consumer products, including household and personal care, food and beverage.  Greg also serves as the global coordinating partner and transactions leader for a number of leading multinational consumer product companies.


EY - Portrait image Jeff Greene

Jeff Greene

EY Global Transactions Leader, Life Sciences
Transaction Advisory Services

Jeff Greene is a principal in the EY transaction advisory services practice and the global transactions leader for life sciences. With more than 25 years of transaction experience, he supports global companies with their due diligence, tax, integration, carve-out and valuation needs in North America, Europe and Asia. He provides strategic valuation advice in mergers and acquisitions, financings and restructurings, and is a recognized expert witness in federal, district, bankruptcy and tax courts on valuation, fairness and solvency matters.

Jeff has authored articles and book chapters on valuation, solvency, due diligence and performance measurement, including: Optimizing the corporate portfolio in a buyer's market, The Valuation-Savvy Pharma Enterprise and Toward World-Class Divestitures. He is a member of the editorial advisory board of the journal Valuation Strategies, and has served as a guest faculty member at seminars held by the Practicing Law Institute and National Investor Relations Institute.